<DOC>
	<DOCNO>NCT02780687</DOCNO>
	<brief_summary>Primary objective investigate efficacy term 6 month progression free survival ( PFS6 ) objective response rate ( ORR ) afatinib , patient advanced/metastatic urothelial tract carcinoma progress despite prior platinum base chemotherapy . Other measure efficacy include progression free survival ( PFS ) , overall survival ( OS ) , disease control rate ( DCR ) , duration objective response ( DOR ) , tumour shrinkage .</brief_summary>
	<brief_title>Afatinib Monotherapy Patients With ERBB ( Epidermal Growth Factor Family Receptors ) -Deregulated Metastatic Urothelial Tract Carcinoma After Failure Platinum Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Urologic Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Recurrent metastatic urothelial cancer Patients must fail prior platinum base treatment ( adjuvant 1st line ) Archival tissue sample available biomarker test prescreening tissue banking . Patients complete prescreening biomarker analysis fulfill follow : Cohort A tumour show ERBB2 ( epidermal growth factor family receptor 2 ) ERBB3 mutation , ERBB2 gene amplification ; Cohort B tumour show EGFR ( Epidermal Growth Factor Receptor ) amplification . Further inclusion criterion apply Exclusion criterion : Prior use EGFR , ERBB2 ERBB3 target treatment Chemotherapy within 4 week prior start study treatment . Biological therapy investigational agent within 4 week prior start study treatment prior pass 5 halflives , i.e . systemic clearance , whatever come first Known brain metastasis sign hereof , uncontrolled spinal cord compression leptomeningeal carcinomatosis Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>